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Background: Multi attribute utility instruments (MAUIs) are preference-based measures that 
comprise a health state classification system (HSCS) and a scoring algorithm that assigns a utility 
value to each health state in the HSCS. When developing a MAUI from a health-related quality 
of life (HRQOL) questionnaire, first a HSCS must be derived. This typically involves selecting 
a subset of domains and items because HRQOL questionnaires typically have too many items 
to be amendable to the valuation task required to develop the scoring algorithm for a MAUI. 
Currently, exploratory factor analysis (EFA) followed by Rasch analysis is recommended for 
deriving a MAUI from a HRQOL measure.
Aim: To determine whether confirmatory factor analysis (CFA) is more appropriate and efficient 
than EFA to derive a HSCS from the European Organisation for the Research and Treatment 
of Cancer’s core HRQOL questionnaire, Quality of Life Questionnaire (QLQ-C30), given its 
well-established domain structure.
Methods: QLQ-C30 (Version 3) data were collected from 356 patients receiving palliative 
radiotherapy for recurrent/metastatic cancer (various primary sites). The dimensional structure 
of the QLQ-C30 was tested with EFA and CFA, the latter informed by the established QLQ-
C30 structure and views of both patients and clinicians on which are the most relevant items. 
Dimensions determined by EFA or CFA were then subjected to Rasch analysis.
Results: CFA results generally supported the proposed QLQ-C30 structure (comparative fit 
index =0.99, Tucker–Lewis index =0.99, root mean square error of approximation =0.04). EFA 
revealed fewer factors and some items cross-loaded on multiple factors. Further assessment 
of dimensionality with Rasch analysis allowed better alignment of the EFA dimensions with 
those detected by CFA.
Conclusion: CFA was more appropriate and efficient than EFA in producing clinically inter-
pretable results for the HSCS for a proposed new cancer-specific MAUI. Our findings suggest 
that CFA should be recommended generally when deriving a preference-based measure from a 
HRQOL measure that has an established domain structure.
Keywords: multi attribute utility instrument, health state classification system, confirmatory 
factor analysis, exploratory factor analysis, European Organisation for the Research and Treat-
ment of Cancer QLQ-C30
Introduction
Multi attribute utility instruments (MAUIs) are preference-based quality of life mea-
sures that can be used in cost–utility analysis.1 MAUIs have two components. The first 
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is a “health state classification system” (HSCS), comprising 
core domains of health-related quality of life (HRQOL), 
each comprising a number of levels (eg, poor, moderate, 
good). For example, the widely used MAUI, EQ-5D, has 
five dimensions, each with three levels.2 These dimensions 
(or “attributes”) and levels define the HSCS. Thus, the HSCS 
of the EQ-5D comprises 35=243 unique health states. The 
second component is a scoring algorithm, which assigns a 
utility value to each health state, based on the valuation elic-
ited, using a preference-based assessment method, typically 
from a general population sample.
MAUIs have previously been derived from various 
HRQOL measures.3–5 This typically involves two stages. The 
first stage involves selecting a subset of domains and items 
from the HRQOL measure to form a HSCS. This reduc-
tion stage is required because HRQOL measures typically 
include more items and domains than is manageable in the 
preference-based valuation exercise required for the second 
stage, in which a sample of health states is valued and an 
algorithm derived for estimating the utility of all possible 
health states.
The European Organisation for Research and Treatment 
of Cancer’s (EORTC) core Quality of Life Questionnaire 
(QLQ-C30)6 is one of the most widely used cancer-specific 
HRQOL instruments, but is not a preference-based measure7 
and, therefore, cannot be used in cost–utility analysis. One 
solution is to “map” the QLQ-C30 to a preference-based 
 measure.8 A more theoretically rigorous approach is to 
develop a cancer-specific MAUI from the QLQ-C30, as has 
been done by Rowen et al.9
Rowen et al applied the methods of Young et al,10 starting 
with exploratory factor analysis (EFA) to identify clusters 
of correlated items as a prerequisite to Rasch analysis to 
assess psychometric properties of items relevant to their 
performance in a MAUI.5,10 Items that did not perform well 
on various psychometric criteria related to EFA and/or Rasch 
procedures were excluded, and then one or two items from 
each domain were retained as the basis for the HSCS for 
the MAUI. The main advantages of this method are that the 
resulting classification system represents the dimensionality 
of the measure using observed data. Further, this method can 
be used for any measures, regardless of whether it has an 
established dimensional structure. One crucial disadvantage 
is that EFA will produce only factors, as opposed to clinically 
coherent HRQOL dimensions.
When a HSCS is to be derived from a questionnaire with 
an established dimensional structure that is psychometrically 
robust and clinically sensible, arguably a  confirmatory 
approach to the question of dimensionality is more appropri-
ate than an exploratory approach. The QLQ-C30 is such an 
instrument. The confirmatory approach involves the positing 
of a specific dimensional structure (the conceptual model) 
that is tested with confirmatory factor analysis (CFA). This 
has three advantages over the exploratory approach. First, 
many of the arbitrary decisions involved in EFA (eg, method 
of extraction, method of rotation, number of factors to 
extract) are removed, replaced instead with more theoreti-
cally or clinically driven decisions, such as which items are 
hypothesized to load on which factors. Second, without a 
priori clinical guidance, any given solution may lack clini-
cal cohesion. Third, the positing of a specific model allows 
clinical considerations – which we define here as the views of 
both patients and clinicians about issues relevant to HRQOL 
in cancer – to play a more structured a priori role than EFA 
can allow. Certain items may be included in or excluded 
from the model a priori, based on clinical or theoretical 
considerations, meaning that clinical considerations can be 
built in to the general method of item assessment, rather than 
acting as a post hoc, context-specific activity. Items deemed 
important in the trade-off between HRQOL and survival may 
thus be selected solely according to clinical  considerations. 
For such items, clinical considerations would override 
statistical criteria, ensuring that the condition-specific 
preference-based measure contains symptoms of particular 
relevance to that condition. In cancer, these include fatigue, 
pain, and nausea.11,12
The aim of the current paper is to compare confirmatory 
with exploratory approaches in deriving a cancer-specific 
MAUI from the QLQ-C30, given its well-established domain 
structure. Note that the objective of the analyses reported in 
this paper was not to develop a specific HSCS, but rather to 
refine and make further recommendations on the appropriate 
methodology for defining the dimension structure for the 
MAUI, focusing on step 1 of the seven-step item selection 
procedure described by Young et al.10
Methods
Ethical approval for this study was granted by the University 
of Sydney Human Research Ethics Committee (Protocol 
Number 13207).
Quality of life instrument
The European Organisation for the Research and Treatment 
of Cancer QLQ-C30 (Version 3) is a multidimensional instru-
ment containing 30 items assessing symptoms, functioning, 
and overall HRQOL (Table 1). Its validity and reliability are 
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Table 1 The 30 items of the Quality of life Questionnaire c30 
and the scalesa to which they belong
Item Item stem wording Scale
1 Do you have any trouble doing  
strenuous activities, like carrying a  
heavy shopping bag or a suitcase?
PF
2 Do you have any trouble taking a  
long walk?
PF
3 Do you have any trouble taking a  
short walk outside of the house?
PF
4 Do you need to stay in bed or a  
chair during the day?
PF
5 Do you need help with eating,  
dressing, washing yourself,  
or using the toilet?
PF
6 Were you limited in doing either  
your work or other daily activities?
RF
7 Were you limited in pursuing your  
hobbies or other leisure time  
activities?
RF
8 Were you short of breath? Dyspnea (s)
9 have you had pain? Pain
10 Did you need to rest? Fatigue
11 have you had trouble sleeping? insomnia (s)
12 have you felt weak? Fatigue
13 have you lacked appetite? appetite loss (s)
14 have you felt nauseated? nausea/vomiting
15 have you vomited? nausea/vomiting
16 have you been constipated? constipation (s)
17 have you had diarrhea? Diarrhea (s)
18 Were you tired? Fatigue
19 Did pain interfere with your  
daily activities?
Pain
20 Have you had difficulty in  
concentrating on things, like reading  
a newspaper or watching television?
cF
21 Did you feel tense? eF
22 Did you worry? eF
23 Did you feel irritable? eF
24 Did you feel depressed? eF
25 Have you had difficulty remembering  
things?
cF
26 has your physical condition  
or medical treatment interfered  
with your family life?
sF
27 has your physical condition  
or medical treatment interfered  
with your social activities?
sF
28 has your physical condition  
or medical treatment caused  
you financial difficulties?
Financial 
difficulties (S)
29 how would you rate your overall  
health during the past week?
global
30 how would you rate your overall  
quality of life during the past week?
global
Notes: aThere are five multi-item functioning scales (PF, RF, CF, EF, and SF); three 
multi-item symptom scales (fatigue, pain, and nausea/vomiting); a global health/
quality of life scale; and six single-item scales (s).
Abbreviations: cF, cognitive functioning; eF, emotional functioning; PF, physical 
functioning; RF, role functioning; sF, social functioning.
well established.6,13 Responses to items 1–28 are made on 
a four-point scale (1= “Not at all”, 2= “A little”, 3= “Quite 
a bit”, 4= “Very much”), and responses to items 29 and 
30 (global health and quality of life items) are made on a 
seven-point scale (1= “Very poor” and 7= “Excellent”). 
Items 6–30 have a recall period of the past week; no recall 
period is specified for items 1–5 (Physical Functioning). 
The 30 items form five functioning scales, three multi-item 
symptom scales, five single-item symptom scales (plus a 
financial difficulties item), and a global health status and 
HRQOL scale (Table 1).
Data set
A secondary analysis was conducted on data collected with 
the QLQ-C30 (Version 3) from a sample of 356 patients 
(53% Norwegian and 47% Swedish) with stage IV/
recurrent/metastatic cancer from a variety of primary sites 
(36% prostate, 30% breast, 11% lung, and 23% other), all 
undergoing palliative radiotherapy in a randomized clini-
cal trial comparing two fractionations.14 The mean age was 
66.77 years (standard deviation =10.60, range 31.59–90.32) 
and 43.8% were female. Analysis was conducted on the 316 
of 356 patients who had complete QLQ-C30 data. These 
patients did not differ from those excluded on any of the 
key variables (assessed with chi-squared test for treatment 
arm [P=1.00], country [P=0.77], sex [P=0.06], and primary 
cancer site [P=0.72]).
analysis
Exploratory versus confirmatory factor analysis
EFA is a statistical procedure in which variables are 
grouped into relatively independent subsets based on their 
intercorrelations, without any prior assumptions about the 
composition of these subsets. In contrast, CFA involves 
testing a prespecified arrangement of items into subsets, 
guided by a conceptual model. EFA and CFA were con-
ducted to assess the dimensional structure of the QLQ-C30 
and the results compared. The model of HRQOL tested 
using CFA was based on both the established structure 
of the QLQ-C3015 and clinical considerations (described 
below).
Three items were excluded a priori from both the EFA 
and CFA. Item 28 (financial difficulties) was excluded 
from all analyses as it is neither a symptom nor a measure 
of functioning. The two global items (29 and 30) were also 
excluded because each item in the HSCS should represent a 
specific domain of HRQOL (functioning or symptom) rather 
than global quality of life.3
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exploratory approach
For the initial EFA, principal axis factoring (PAF) was used 
with a direct oblimin rotation to allow factors to be corre-
lated. The suitability of the data for EFA was assessed using 
the  Kaiser–Myer–Olkin measure of sampling adequacy 
and the Bartlett test of sphericity. Criteria for suitability 
are Kaiser–Myer–Olkin .0.8 and a P-value for Bartlett’s 
χ2 of less than 0.01.16 Parallel analysis,17 using the Monte 
Carlo PCA for Parallel Analysis software, was used to 
inform selection of factors. This involves computing mean 
eigenvalues from randomly generated sets of data (N=1,000) 
of the same size (number of items and number of observa-
tions) as the observed data set. Any factor obtained from 
the observed data set with an eigenvalue exceeding the cor-
responding eigenvalue generated from parallel analysis was 
considered for selection. A scree plot was also inspected. 
An item was considered to load on a factor if it had a pat-
tern matrix loading greater than 0.3 and did not load on any 
other component.
We also conducted a sensitivity analysis involving all 
15 combinations of: two extraction methods (PAF, maximum 
likelihood), and principal components analysis, and five 
rotation methods (oblimin, promax, varimax, equamax, and 
quartimax), comparing the degree of variability in solutions 
obtained due to variation in these technical parameters.
Confirmatory approach
a priori clinical considerations
The guiding principle here was to consider which aspects 
of functioning, symptoms, and side effects should be 
included in the HSCS, and hence the utility function of 
cancer-specific MAUI, in order for it to have face validity 
for economic evaluation of cancer treatments. Inclusion 
of dimensions was determined by three considerations: 
a) the dimensions available in the QLQ-C30; b) the patient’s 
perspective (which symptoms, side effects, and aspects of 
functioning are considered important by patients in their 
overall assessment of quality of life); and c) the clinician’s 
perspective (which dimensions matter when assessing the 
value of alternative treatments). Previous research has 
shown that patients13 and clinicians7 consider pain, fatigue, 
nausea/vomiting, constipation, and diarrhea to be important. 
All are available in the QLQ-C30. It is also well established 
that the various aspects of functioning are correlated with 
measures of overall quality of life.14 Regression analysis 
has also revealed certain domains to be strong predictors 
of global quality of life, eg, emotional functioning and 
fatigue.18,19
The primary difference between clinical considerations 
using the confirmatory approach versus previous exploratory 
approaches is that in the confirmatory approach, they are 
incorporated a priori as part of the procedure to assess items 
for inclusion.
established structure of the QlQ-c30
We defined the “conceptual model” as the arrangement of 
items on the QLQ-C30 into domains based on the established 
structure of the QLQ-C306 and the clinical considerations 
described above. We defined the “measurement model” as 
the subset of the conceptual model that was empirically 
tested using CFA.
The conceptual model to be used as a starting point for the 
QLQ-C30 was thus composed of the following eight latent 
variables and five single-item domains:
Functioning: physical functioning (items 1–5); role function-
ing (items 6 and 7); emotional functioning (items 21–24); 
social functioning (items 26–27); and cognitive functioning 
(items 20 and 25).
Symptoms: pain (items 9 and 19); fatigue (items 10, 12, and 
18); nausea and vomiting (items 14 and 15); dyspnea (item 8); 
sleep (item 11); appetite (item 13); constipation (item 16); 
and diarrhea (item 17).
Items included a priori in the conceptual model and therefore 
excluded from measurement model: dyspnea, sleep, appetite, 
constipation, and diarrhea were considered of sufficient 
clinical importance for consideration in the HSCS, but as 
these domains are represented by single items (8, 11, 13, 
16, and 17, respectively), these items were excluded from 
the measurement model.
CFA based on the conceptual models described above 
was conducted using the mean- and variance-adjusted 
weighted least squares estimation method (as recommended 
for ordinal data)20 in Mplus Version 6. Correlations amongst 
the latent variables were not constrained, while correlations 
between error terms were fixed to 0. The fit of the model to 
the data was assessed using the following indices and their 
corresponding widely accepted guidelines indicating good 
model fit:21 chi-squared statistic/degrees of freedom (less 
than 2); comparative fit index (.0.95); Tucker–Lewis index 
(.0.95); root mean square error of approximation (,0.05). 
If model fit was poor on any one of the measures, then factor 
loadings and residual correlations (those .0.1 considered 
noteworthy)22 were examined in order to determine alterations 
to the model that improved fit. Modification indices were 
also examined to determine what other parameters might 
be estimated. The model was modified and retested until a 
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model was obtained that was conceptually meaningful and 
also adequately fitted the data.
item assessment using Rasch analysis
Young et al10 used a variety of techniques to select or reject 
items for the HSCS. These methods use Rasch analysis within 
dimensions identified by EFA. To address the aims of this 
paper, we conduct the Rasch analyses separately for the fac-
tor solutions obtained from EFA and CFA to further explore 
the consequence of these two approaches when applying 
Young et al’s method to the QLQ-C30. These techniques are 
described in detail by Young et al10 and interested readers 
are referred to step 2 of their guidance for deriving a MAUI. 
These are summarized briefly below.
In Rasch analysis, observed responses to items are assumed 
to reflect an underlying latent variable, such that the probability 
of endorsing an item is a monotonic increasing function of the 
underlying latent variable. Items that met the criteria described 
below were deemed to conform to the Rasch model23 and were 
therefore retained for consideration in the HSCS.
All Rasch analyses were conducted using RUMM 203024 
and were performed separately for the dimensions identified 
using EFA and CFA. All procedures and guidelines were con-
sistent with those recommended by Pallant and Tennant.25 The 
initial stage of Rasch analysis was conducted with the aim of 
determining whether any of the items exhibited problems with 
fit to the model, item response threshold ordering, or differen-
tial item functioning.25 Local dependence was also assessed. 
Any items that exhibited such problems were considered for 
exclusion from the HSCS. See the Supplementary materials 
for further details regarding these criteria.
Results
exploratory approach
Table 2 provides a summary of the results from the primary 
EFA (PAF extraction and oblimin rotation) and related 
Table 2 summary of item statistics based on the dimensions established using exploratory factor analysis
Item Factors and loadings (exploratory  
factor analysis)a
Rasch
Location Item fit Differential item 
functioningb
Local 
dependencycFactor 1 Factor 2 Factor 3
1 0.65 0.00 0.01 -0.92 0.88 sex, sited
2 0.75 -0.07 -0.07 -1.23 -1.34 3
3 0.82 -0.06 -0.15 0.96 0.06 2
4 0.65 0.03 0.14 0.14 0.73 10
5 0.52 -0.02 -0.05 3.40 0.95
6 0.86 -0.08 0.02 -0.81 -3.89 site 7
7 0.77 0.02 -0.02 -0.51 -1.37 6
8 0.15 0.17 0.08 not included in Rasch analysis (weak factor loadings)
9 0.49 0.06 0.05 Misfit
10 0.53 0.26 0.25 -0.42 0.59 4
11 -0.02 0.34 0.02 Misfit
12 0.25 0.38 0.34 -0.97 -0.37 18
13 0.01 0.12 0.62 -0.05 0.34
14 -0.11 0.03 0.83 0.63 0.28 site 15
15 -0.11 -0.01 0.77 1.64 -1.73 14
16 0.14 -0.03 0.18 not included in Rasch analysis (weak factor loadings)
17 0.02 -0.07 0.29 not included in Rasch analysis (weak factor loadings)
18 0.24 0.36 0.36 -1.26 -0.05 12
19 0.68 0.11 -0.02 -0.62 1.51
20 0.15 0.41 0.29 Misfit
21 -0.01 0.83 -0.10 0.28 0.29 sex
22 -0.01 0.91 -0.23 -0.28 -1.31 sex, site
23 -0.02 0.60 -0.01 Misfit
24 -0.05 0.77 0.04 -0.001 1.49
25 0.08 0.27 0.27 not included in Rasch analysis (weak factor loadings)
26 0.15 0.35 0.09 Misfit
27 0.42 0.24 0.13 Misfit
Notes: Rasch statistics are those obtained from the final analyses, ie, those with misfitting items removed. aPrincipal axis factoring extraction, direct oblimin rotation; 
bgrouping variables exhibiting differential item functioning for the item are listed in this column; cvalues in this column represent numbers of items with which the item has a 
residual correlation following Rasch analysis; dcancer sites included prostate, breast, lung, and other.
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Rasch analyses. The inter-item correlations were adequate 
for factor analysis (Kaiser–Myer–Olkin =0.892; Bartlett’s 
χ2=3,993.58, P,0.0005). Parallel analysis suggested the 
extraction of three factors, and this was supported by inspec-
tion of the scree plot. Items 8 (dyspnea), 16 (constipation), 
17 (diarrhea), and 25 (memory) loaded weakly on all fac-
tors, while cross-loadings were observed for items 12 and 
18 (both fatigue items).
The three factors identified for subsequent Rasch analysis 
were as follows:
•	 EFA Factor 1. Items 1–7, 9, 10, 19, and 27 (encompassing 
the physical and role functioning domains, the two pain 
items, one of the three fatigue items, and one of the two 
social functioning items);
•	 EFA Factor 2. Items 11, 20–24, and 26 (encompassing the 
emotional functioning domain, the insomnia item, one of 
the two cognitive functioning items, and one of the two 
social functioning items); and
•	 EFA Factor 3. Items 12–15 and 18 (encompassing two 
of the three fatigue items, the appetite loss item, and the 
two nausea/vomiting items). The two cross-loading items 
(fatigue 12 and 18) were assigned to this factor because 
they are symptoms that are more closely related to the 
items on this factor than Factor 2.
The results of EFA differed slightly depending on the 
extraction and rotation method used. Using all 15 combina-
tions of methods: items 1–7, 9, and 19 loaded on Factor 1; 
items 11, 21–24, and 26 loaded on Factor 2; items 13–15 
loaded on Factor 3; and items 8 and 16 exhibited weak load-
ings on all factors. There were a few noteworthy differences. 
Items 17 (diarrhea, Factor 3) and 25 (memory, Factor 2/
Factor 3) had stronger loadings for PCA than for PAF and 
maximum likelihood, to the extent that, using a loading 
cutoff of 0.3, they would have been comfortably included 
in the PCA solution, but not PAF or maximum likelihood. 
For items 12 (weak) and 18 (tired), for all extraction meth-
ods loadings were strongest for Factors 2 and 3 except for 
when quartimax rotation was used; in this case, Factor 1 
exhibited the dominant loadings. For items 10 (rest) and 
27 (interfered with social activities), Factor 1 exhibited the 
dominant loading but strength of cross-loadings differed 
between extraction/rotation combinations, and the same 
for item 20 (concentration) except that Factor 2 dominated. 
Results are available from the authors on request.
Confirmatory approach
The factor loadings obtained from CFA are presented 
in Table 3. The loadings of all items on their respective 
factors were relatively strong and all statistically  significant 
(P,0.001). Model fit was adequate (χ2/df =2.79, com-
parative fit index =0.964, Tucker–Lewis index =0.953, 
root mean square error of approximation =0.075). Residual 
correlations and modification indices suggested additional 
relations between items 4 and 10, and items 2 and 3. Items 4 
and 10 cover similar content (needing to rest), as do items 2 
and 3 (trouble taking a long walk and short walk). Because 
items 4 and 10 were posited to load on different factors 
(Physical Functioning and Fatigue, respectively) cross-
loadings were introduced for these items and domains, 
whereas because items 2 and 3 were posited to load on 
the same factor  (Physical Functioning), the covariance 
between their error terms was estimated. Estimation of 
these cross-loadings and covariance resulted in improved 
model f it (χ2/df=1.51, comparative f it index =0.990, 
Tucker–Lewis index =0.987, root mean square error of 
approximation =0.040).
The correlations between the eight factors are displayed 
in Table 4. Most noteworthy was the very high (0.86) 
correlation between role and physical functioning, sug-
gesting that the items in these two factors may reflect a 
single factor.
Although the hypothesized eight-factor structure of the 
QLQ-C30 was generally supported, it was decided that 
the physical functioning domain (items 1–5) be combined 
with the role functioning domain (items 6 and 7) as well as 
item 10 for the purpose of Rasch analysis, based on the results 
above. Item 10 was not included in the fatigue domain (with 
items 12 and 18) for Rasch analysis. The other domains were 
subjected to Rasch analysis without any change from the 
factor specified a priori.
Rasch analysis
Based on eFa
The factor-level results of the Rasch analysis for the factors 
derived using EFA are shown in the left panel of Table 2. This 
table illustrates that Factors 1 and 2 required the removal 
of items to achieve adequate fit to the Rasch model. High 
residual correlations were observed between items 2 (long 
walk) and 3 (short walk), items 4 (stay in bed) and 10 (need 
to rest), items 6 (daily activities) and 7 (leisure activities), 
items 12 (weak) and 18 (tired), and items 14 (nausea) and 
15 (vomiting). The correlations between items 6 and 7, 
items 12 and 18, and items 14 and 15 were unsurprising, 
as the traditional QLQ-C30 domain structure treats these 
as separate domains (role functioning, fatigue, and nausea/
vomiting, respectively). The other two pairs of residual 
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Table 3 summary of item statistics based on the dimensions established using cFa
Item A priori factors, guided  
by conceptual model
CFA loadings Rasch
Location Item fit Differential item  
functioninga
Local  
dependencyb
1 Physical functioning 0.78 -1.01 0.79 sex, sitec
2 Physical functioning 0.80 -1.33 -1.64 3
3 Physical functioning 0.79 0.90 -0.13 2
4 Physical functioning 0.58, 0.31d 0.06 0.71 10
5 Physical functioning 0.76 3.39 0.76
6 Role functioning 0.94 -0.90 -3.62 site 7
7 Role functioning 0.90 -0.59 -0.48 6
9 Pain 0.72 -0.38 1.42
10 Fatigue 0.66, 0.39d -0.52 0.97 4
12 Fatigue 0.87 0.22 -0.07 site
14 nausea and vomiting 0.94 -1.20 -0.72 site
15 nausea and vomiting 0.92 1.20 -0.21 site
18 Fatigue 0.88 -0.22 0.38
19 Pain 0.97 0.38 0.24
20 cognitive functioning 0.89 -0.10 0.52
21 emotional functioning 0.89 0.28 0.29 sex
22 emotional functioning 0.88 -0.28 -1.31 sex, site
23 emotional functioning 0.67 Misfit
24 emotional functioning 0.86 -0.001 1.49
25 cognitive functioning 0.62 0.10 1.15
26 social functioning 0.63 0.323 1.03
27 social functioning 0.87 -0.323 0.71 site
Notes: The results are for the refined model, in which loadings for items 4 and 10 on both physical functioning and the covariance between items 2 and 3 were estimated. 
Rasch statistics are those obtained from the final analyses, ie, those with misfitting items removed. agrouping variables exhibiting differential item functioning for the item are 
listed in this column; bvalues in this column represent numbers of items with which the item has a residual correlation following Rasch analysis; ccancer sites included prostate, 
breast, lung, and other; destimate of loading on the non–a priori factor, ie, fatigue for item 4, physical functioning for item 10.
Abbreviation: CFA, confirmatory factor analysis.
Table 4 Correlations between factors obtained from the confir-
matory factor analysis
PF RF EF SF CF Pain Fatigue
RF 0.90
eF 0.28 0.32
sF 0.60 0.62 0.57
cF 0.44 0.50 0.59 0.65
Pain 0.73 0.78 0.39 0.58 0.43
Fatigue 0.52 0.57 0.59 0.61 0.79 0.54
nV 0.19 0.30 0.25 0.37 0.48 0.33 0.58
Abbreviations: cF, cognitive functioning; eF, emotional functioning; nV, nausea 
and vomiting; PF, physical functioning; RF, role functioning; sF, social functioning.
correlations are also unsurprising, given the content of the 
items. No individual items exhibited misfit or disordered 
thresholds. Items 1, 6, 14, 21, and 22 exhibited differential 
item functioning (Table 2).
Based on cFa
Table 3 provides a summary of the results from the CFA 
and related Rasch analyses, and the factor-level results are 
shown in the right panel of Table 3. Only Factor 2 required the 
removal of items to achieve adequate fit to the Rasch model 
(see Table 5 for factor-level Rasch analysis statistics). High 
residual correlations were observed between items 2 (long 
walk) and 3 (short walk), items 4 (stay in bed) and 10 (need 
to rest), and items 6 (daily activities) and 7 (leisure activities). 
No individual items exhibited misfit or disordered thresholds. 
Items 1, 6, 12, 14, 15, 21, 22, and 27 exhibited differential 
item functioning (see Table 3).
Discussion
The factor structures obtained from EFA and CFA followed 
by Rasch analysis were similar; however, CFA produced 
more readily interpretable solutions than EFA. Many of 
the discrepancies between the hypothesized factor structure 
in CFA and the clusters of items that emerged from EFA 
were eliminated when the factors obtained from EFA were 
subjected to Rasch analysis. For example, EFA Factor 2 
originally comprised items 11, 20–24, and 26, but following 
Rasch analysis, this dimension was reduced to the emotional 
functioning domain of the QLQ-C30 (items 21–24). Item 23 
was then further found to misfit and removed. The key point 
is that the confirmatory approach arrived at this solution more 
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Table 5 summary of the factor-level statistics based on the 
dimensions established using exploratory (top panel) and 
confirmatory (bottom panel) factor analyses
Exploratory factor analysis
Factor 1 
(1–7, 9, 10, 19, 27)
initial: 
Item fit =2.44 (poor) 
Person fit =1.04 (good) 
Final (items 9, 27 removed): 
Item fit =1.71 (poor)a 
Person fit =0.92 (good)
Factor 2 
(11, 20–24, 26)
initial: 
Item fit =2.82 (poor) 
Person fit =1.11 (good) 
Final (items 11, 20, 23, 26 removed): 
Item fit =1.41 (good) 
Person fit =1.34 (good)
Factor 3 (12–15, 18) initial: 
Item fit =0.85 (good) 
Person fit =0.79 (good)
Confirmatory factor analysis
Factor 1 (1–7, 10) initial: 
Item fit =1.60 (poor)a 
Person fit =0.85 (good)
Factor 2 (21–24) initial: 
Item fit =2.28 (poor) 
Person fit =1.13 (good) 
Final (item 23 removed): 
Item fit =1.41 (good) 
Person fit =1.34 (good)
Factor 3 (26, 27) initial: 
Item fit =0.23 (good) 
Person fit =0.77 (good)
Factor 4 (20, 25) initial: 
Item fit =0.44 (good) 
Person fit =1.08 (good)
Factor 5 (9, 19) initial: 
Item fit =0.83 (good) 
Person fit =0.97 (good)
Factor 6 (12, 18) initial: 
Item fit =0.32 (good) 
Person fit =0.99 (good)
Factor 7 (14, 15) initial: 
Item fit =0.36 (good) 
Person fit =0.85 (good)
Notes: Item fit for both item and person represent the fit residual standard 
deviation, where a value greater than 1.5 is considered poor. aAlthough item fit was 
poor, no individual item exhibited misfit.
the inclusion or exclusion of item 17 (diarrhea) and different 
decisions about which domain should include the fatigue items 
(12 and 18) may affect the composition of the HSCS.
Some aspects of the EFA solution were difficult to 
 interpret. For example, the social functioning items loaded 
on different factors; specifically, item 26 (interfered with 
family life) loaded with physical/role functioning items 
and item 27 (interfered with social activities) loaded with 
emotional functioning items. Similarly, fatigue items loaded 
with nausea, vomiting, and lack of appetite. Although 
post hoc explanations of these relations are possible, and 
may well be causal (as discussed below), it is difficult to 
justify the inclusion of such items in the same domain for 
the purpose of selecting items for a utility instrument. For 
example, whether respondents experience interference with 
social activities is arguably a substantively different issue to 
whether respondents feel tense, and it seems inappropriate 
for these two items to be competing candidates for inclusion 
to represent the same factor in the HSCS. This means that 
judgment must be applied when using EFA as the factor 
analysis will establish “factors”, and clinical input and inter-
pretation is required to derive the “ dimensions” from these 
factors. In contrast, in the CFA approach this guidance is 
provided at the outset to inform the  factor analysis, meaning 
that the results directly represent the dimensionality of the 
measure. It is worth noting that three of the four items with 
weak EFA loadings (items 8, 16, and 17) were also three 
of the five items (along with items 11 and 13) that were 
excluded from the measurement model a priori.
EFA produced a solution that combined the physical 
(items 1–5) and role functioning domains (items 6 and 7) 
of the QLQ-C30. In the CFA, model fit was adequate with 
these two domains kept separate, although the two domains 
were very highly correlated. Residual PCA, as part of the 
Rasch analysis, confirmed that these are in fact two separate 
domains. One possible reason for this is that items 6 and 7 
differ from items 1–5 in their “item difficulty”, a phenomenon 
that would be more readily identified by Rasch analysis than 
factor analysis. An alternative explanation is that there exists 
a higher order factor that encompasses both physical and role 
functioning, or that there is some causal relation between 
these two factors. These latter possibilities are addressed 
further below, but are in any case more readily addressed 
using a confirmatory than an exploratory approach.
The confirmatory approach employed in the present 
analysis provided a structured role for clinical considerations 
and an explicitly articulated relation to the statistical and psy-
chometric criteria used in the item selection process, whereas 
efficiently than the exploratory approach. Furthermore, the 
two adjustments to the measurement model tested in CFA 
that were required (namely, the estimation of the relations 
between items 4 and 10 and items 2 and 3) were readily 
identified and accommodated in the model.
The EFA results were found to differ somewhat depend-
ing on the method of extraction and rotation employed. 
Although these differences were not large, they may have 
had some impact on the item selection process. For example, 
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in the previously employed exploratory approach, clinical 
considerations were less formally specified and explicitly 
integrated with the statistical analysis.
Rowen et al9 in the derivation of EORTC 8D employed 
the input of a clinician to ensure the statistical results made 
sense clinically. In the present analysis, we have developed 
the structured integration of clinical considerations further 
into the predefined set of judgment criteria. Furthermore, 
by identifying certain items as of interest a priori allows 
a structured approach to the selection of items that are of 
clinical relevance but may not perform adequately in the 
statistical analysis. For example, although few respondents 
in this data set reported problems with diarrhea (item 17), 
the a priori inclusion of this item in the conceptual model 
allowed clinical considerations to override the statistical 
criteria. The importance of this is illustrated by the ALTTO 
trial, in which diarrhea was a critical side effect distinguish-
ing trastuzimab from lapatinib.19 The omission of diarrhea 
on statistical grounds, in this case, would result in the loss 
of potentially important information from the HSCS. This 
is not to say that the exploratory approach has little value in 
establishing the domain structure for a HSCS, particularly in 
cases where an instrument does not have a well-established 
domain structure.
limitations
Our analysis was conducted on a sample of patients who were 
either Norwegian or Swedish, with two-thirds having primary 
cancer sites that were either breast or prostate and all having 
recurrent/metastatic cancer. Different results may be obtained 
from samples of patients with different profiles. Indeed, the 
EFA solution we obtained differed from that of Rowen et al,9 
who analyzed data from newly diagnosed multiple myeloma 
patients. Their factor solution may also have differed from 
ours for reasons related to analysis details, eg, use of parallel 
analysis to select the number of factors in the present case 
versus eigenvalues and variance explained. The conclusions 
drawn from the present analysis would be strengthened by 
replication using data from patients with a variety of cancer 
sites, stages, and treatments, and from various countries, 
using identical statistical techniques.
Conclusion
A confirmatory approach to determining dimensionality for 
the construction of a HSCS was found to be more efficient 
and to produce a more readily interpretable domain structure 
for the QLQ-C30. The confirmatory aspect of this prototype 
analysis will now be applied on a much larger scale as part 
of the Multi-Attribute Utility in Cancer (MAUCa) project, 
involving the pooling of a large number of international data 
sets covering a range of countries, cancer sites, and stages. 
Based on the results, a definitive HSCS will be determined. 
The results of the present analysis will guide this large-scale 
analysis only inasmuch as they support the use of the par-
ticular method – the specific composition of dimensions and 
psychometric properties of dimensions and items obtained 
will be assessed independently of the results of the present 
analysis. This will pave the way for valuation surveys that 
will provide country-specific utility weights for this HSCS, 
and thereby complete the provision of a preference-based 
measure derived from the QLQ-C30.
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Supplementary material
Rasch analysis criteria
Poor item fit
The overall fit of the Rasch model was examined using the 
item–trait interaction χ2 statistic. Good model fit was indi-
cated by a nonsignificant chi-squared statistic. A Bonferroni 
correction was applied to the criterion of significance with 
the alpha value (0.05) divided by the number of items. The 
presence of misfitting items or persons was indicated by a 
fit residual standard deviation value of 1.5 or above. Items 
with individual Fit Residual values exceeding 2.5 were 
removed from the Rasch analysis. Persons with fit residuals 
that exceeded 2.5 were removed only if they appeared to 
contribute to item misfit. This process was repeated until only 
well-fitting items remained, and the overall goodness of fit 
of the model was nonsignificant. Any items excluded due to 
misfit were kept aside and assessed according to other criteria, 
including descriptive statistics and clinical considerations 
(described to follow).
assessment of response format
An appropriately functioning item requires a response for-
mat that respondents use in a consistent manner. Examining 
response thresholds – the points at which each consecu-
tive response category for an item is equally likely to be 
endorsed – allows the assessment of response format in this 
regard. For an appropriately functioning item, the response 
thresholds between successive categories should be ordered, 
such that the threshold between categories 1 and 2 falls 
below the threshold between categories 2 and 3, and so on. 
A disordered response threshold indicates that respondents 
are not selecting response categories expected according to 
their overall scale score.
invariance of item functioning  
across different groups
For an item to be included in the HSCS, the probability of 
selecting a certain response category for a given value of 
the latent trait should be invariant across groups. If it is not, 
the item exhibits differential item function (DIF). DIF is a 
form of bias in which systematic differences in patterns of 
responding to an item are observed between individuals with 
different characteristics, despite having the same level of the 
latent variable. If two or more groups showed a consistent 
difference in item responses across the range of values for 
the latent variable, this is known as “uniform DIF”. “Non-
uniform DIF” occurs when the differences between groups 
vary over the range of values of the latent variable. In RUMM 
2020, DIF is assessed using two-way analysis of variance, 
with predicted score compared across the different levels 
of the grouping variable and across different levels of the 
latent trait (where individuals are grouped into a number of 
“class intervals” based on their latent trait score [35]). The 
data were examined for DIF across sex and cancer site. (DIF 
across country is an important issue but has been examined 
previously.) Because cross-population comparisons using the 
HSCS are desirable, any items exhibiting DIF were excluded 
from the HSCS.
local dependence
Local dependence among items, indicating an association 
above and beyond that shared by the underlying trait, was 
assessed by inspection of the residual correlation matrix for 
values exceeding 0.3.
